Happy Friday afternoon to everyone on The Street. Here's a snapshot of where markets ended the trading session, plus tomorrow's trade idea delivered to you today.

Sponsored by Centurion Publishing

SHOCKING Footage from Strange South Carolina Facility…

This isn’t some AI data center, government facility, Tesla factory or Amazon plant… But the technology being implemented here could soon begin to usher in $24 trillion of new wealth.

Click here to watch as chief investment analyst Matt McCall reveals exactly what’s going on PLUS his top 3 picks to profit from the massive tech rollout.

MARKET MOVERS

WR Berkley, Amazon, NVIDIA

$AMZN ( ▼ 4.4% ) Amazon Stock and the Mag 7 Are Falling Again. It’s Not Time to Buy, Portfolio Manager Says. (Barron’s)

$WRB ( ▲ 7.45% ) WR Berkley Stock Surges to Record High as Japan's MSI Plans to Take 15% Stake (Investopedia)

$NVDA ( ▼ 1.65% ) Veteran fund manager offers blunt take after Nvidia stock drop (The Street)

$MRK ( ▲ 1.84% ) Merck plans to launch US subcutaneous version of Keytruda on October 1 (Reuters)

$BLCO ( ▼ 5.47% ) Bausch + Lomb announces intraocular lens recall (YF)

OVERHEARD ON THE STREET

Reuters: US consumer spending rebounded 0.4% in February, but core PCE inflation climbed 0.4% (up 2.8% year-on-year), more than expected.

CNBC: Key OpenAI supplier CoreWeave $CRWV ( 0.0% )  IPO’d today on the Nasdaq.

Bloomberg: CK Hutchison $CKHUY ( ▼ 5.0% ) and BlackRock $BLK ( ▼ 2.06% ) may delay the deal to sell the former’s Panama Canal ports to the latter.

WSJ: President Trump warned US automakers not to raise car prices in response to tariffs, threatening unfavorable consequences.

Fortune: Boston Fed President Collins warned tariff-induced inflation "looks inevitable" and said interest rates will likely stay put for longer.

TOMORROW’S TRADE IDEA, TODAY

Slept-On Healthcare Stocks

Sky-High Ceiling

Genetic testing company GeneDx $WGS ( ▼ 2.18% ) is up more than 900% over the past 12 months. But Alger analyst Amy Zhang thinks it could still have much further to go.

That’s not all. The analyst pointed to a handful of unknown healthcare stocks with tons of potential upside. Here’s why the asset management firm thinks it’s time for investors sleeping on the sector to wake up.

Exponential Growth

GeneDx leverages genome sequencing to diagnose rare diseases and identify genetic causes. Last year, its market cap surged from less than $70 million to more than $2 billion, bringing its stock price skyrocketing with it.

But Zhang believes the company is still well-positioned to outpace a growing industry. According to Zhang, GeneDx is primed for faster and cheaper growth than its competitors, all without sacrificing its products' high accuracy standards. 

She believes the company is helping to solve a “very critical problem in health care” and that its growth runway remains long. She expects the market for its services to reach more than $40 billion, which could bring revenue and profits up with it.

Natera & Glaukos

Zhang also pointed to two other little-known stocks, Natera $NTRA ( ▼ 2.94% ) and Glaukos $GKOS ( ▼ 1.57% ) , as potential winners. 

She believes the total addressable market for Natera — another emerging genetic testing player — could reach as high as $60 billion. The analyst is confident in its management’s ability to execute, which is part of why the stock is up some 57% over the past full year. 

For Glaukos, the analyst says the launch of iDose, a sustained-release implant, will be a huge growth driver for the company. Unlike the other names, the glaucoma treatment stock is down more than 20% in 6 months — a potentially attractive entry point.

Sponsored by BOXABL

BOXABL round on StartEngine is closing tomorrow!

Most houses take seven months to complete. BOXABL can put one out of the assembly line every four hours, including electrical, HVAC, and plumbing! Now, the company is raising funds and has made shares available to the public but the round is closing soon on StartEngine!

The company already has two home models and is developing a 20x30 and 20x40 home as part of their Phase 2 plan!

Currently, shares are being offered at $0.80 per share. With a $1,000 minimum investment, you can join 40,000 investors to help solve the housing crisis.

Time is running out, TOMORROW is the last day to invest in BOXABL on StartEngine.

Invest Now!

Disclosure: *This is a paid advertisement for Boxabl’s Regulation A offering. Please read the offering circular here. This is a message from Boxabl

ON OUR RADAR

WSJ: A 7.7-magnitude earthquake in Myanmar killed at least 144 people and caused widespread destruction, with its effects reaching as far as Bangkok.

CNBC: Trump pardoned Nikola $NKLA ( ▲ 110.33% ) founder Trevor Milton, who was convicted in October 2022 for defrauding investors.

Bloomberg: The EU is preparing concessions to Trump to secure the partial removal of US tariffs on its exports, which are set to increase after April 2.

CNN: Americans’ unemployment concerns hit its highest level since 2009, per the University of Michigan’s consumer sentiment survey.

Forbes: The expected Trump-driven M&A boom hasn’t materialized. Is it delayed or dead?

THURSDAY’S POLL RESULTS

Are you bullish or bearish on Perimeter Solutions (PRM) over the next 12 months?

🟨🟨🟨🟨⬜⬜ 🐂 Bullish

🟩🟩🟩🟩🟩🟩 🐻 Bearish

And, in response, you said:

This message is a paid advertisement for Boxabl Inc. The Street Sheet (SS) receives a flat fee from Ad Astra Media totaling up to $5,250. Other than the compensation received for this advertisement sent to subscribers, The Street Sheet and its principals are not affiliated with Boxabl Inc. This advertisement is sponsored by a third-party Reg A crowdfunding issuer and is for informational purposes only. The Street Sheet does not endorse or recommend any specific offering, and this advertisement should not be construed as a recommendation to invest. Investing in securities, including those offered through Reg A crowdfunding, involves risk, including the potential loss of principal. These investments are speculative, illiquid, and may involve a higher degree of risk compared to more traditional investments. The Street Sheet has not verified the information provided by the advertiser, and we encourage readers to conduct their own due diligence and consult with a licensed financial advisor or other qualified professional before making any investment decision. By engaging with this advertisement, you acknowledge that The Street Sheet and its affiliates are not responsible for any decisions or actions taken based on the information provided in this advertisement. All investments carry risks, and past performance is not indicative of future results. Readers should carefully review all information provided by the issuer, including the offering circular and any other available materials, prior to investing. The Street Sheet may receive compensation from the advertiser for promoting this offering. The Street Sheet and its principals do not own any of the stocks or shares mentioned in this email or in the article that this email links to. The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to its accuracy or completeness. Each user of SS chooses to do trades at their sole discretion and risk. SS is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SS receives some sort of compensation is clearly and prominently identified herein as "ad", "Sponsored", or “Together With”. Although we have sent you these advertisements, SS does not specifically endorse any third-party product nor is it responsible for the content, the accuracy, or the completeness of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is in the advertisement. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. This communication from The Street Sheet is for informational purposes only. It is not intended to serve as a recommendation to buy, sell, or hold any security and is not an offer or sale of a security. Information contained within should not be perceived as a research report and is not intended to serve as the basis for any investment decision. Any third-party views reflected herein do not reflect the opinion of The Street Sheet. All investments involve risk and the past performance of a security does not guarantee future results or returns. There is always the potential for financial loss when investing in securities or other financial products. The information contained in this newsletter is subject to change without notice, and we do not undertake any obligation to update it. Readers are encouraged to conduct their own research and due diligence and seek advice from licensed professionals regarding their specific financial needs and circumstances. By reading this newsletter, you agree to hold us harmless from any and all losses, liabilities, costs, or expenses arising from your use or reliance on the information provided. There is no warranty as to the accuracy or completeness of the factual matters included in any advertisement or sponsored content in the newsletter. You have not performed any research on any entity, or its business, that advertises or submits any sponsored content. The Street Sheet is reader-supported. When you buy through links on our site, we may earn a commission.